Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) EBT: 2021-2025

Historic EBT for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to -$12.1 million.

  • SAB Biotherapeutics' EBT fell 16.60% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.6 million, marking a year-over-year increase of 6.57%. This contributed to the annual value of -$41.9 million for FY2024, which is 0.59% up from last year.
  • Latest data reveals that SAB Biotherapeutics reported EBT of -$12.1 million as of Q3 2025, which was down 23.35% from -$9.8 million recorded in Q2 2025.
  • SAB Biotherapeutics' EBT's 5-year high stood at $1.4 million during Q1 2021, with a 5-year trough of -$22.9 million in Q4 2023.
  • In the last 3 years, SAB Biotherapeutics' EBT had a median value of -$9.8 million in 2025 and averaged -$9.8 million.
  • Per our database at Business Quant, SAB Biotherapeutics' EBT slumped by 782.08% in 2023 and then spiked by 56.50% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' EBT (Quarterly) stood at -$11.6 million in 2021, then soared by 32.05% to -$7.8 million in 2022, then slumped by 191.21% to -$22.9 million in 2023, then soared by 56.50% to -$9.9 million in 2024, then decreased by 16.60% to -$12.1 million in 2025.
  • Its last three reported values are -$12.1 million in Q3 2025, -$9.8 million for Q2 2025, and -$10.8 million during Q1 2025.